Bipolar disorder treatment for Palm Beach Gardens — the diagnosis primary care misses.

RECO Integrated Psychiatry is 25 miles south of Palm Beach Gardens — 35 minutes via I-95 from PGA National, Mirasol, and BallenIsles. Our bipolar practice runs full lithium protocols, lamotrigine titrations, and structured second-generation antipsychotic monitoring, with diagnostic evaluations built to catch the bipolar II presentations that primary care and general outpatient psychiatry routinely misclassify as unipolar depression. Board-certified psychiatric prescribers, evidence-based pharmacology, and referrals to therapists with genuine bipolar competency.

Palm Beach Gardens sits 25 miles north of RECO Integrated Psychiatry’s Delray Beach office — roughly 35 minutes down I-95 from PGA National, Mirasol, BallenIsles, Frenchman’s Reserve, and Old Palm. For adults in northern Palm Beach County who suspect bipolar disorder, or who have been treated as unipolar depressives for years without durable response, the specialist-level evaluation available in Delray is meaningfully different from what most general outpatient practices in the area are structured to deliver. RECO’s bipolar disorder treatment program is built around diagnostic precision, mood stabilizer expertise, and the monitoring infrastructure required to run lithium, valproate, and second-generation antipsychotics correctly over the long term.

Bipolar I versus bipolar II versus bipolar spectrum

The load-bearing piece in this population is diagnostic. Bipolar I requires a manic episode — at least seven days of elevated or irritable mood with marked functional impairment, psychotic features, or hospitalization. Bipolar II requires a hypomanic episode of four or more days plus a major depressive episode, without the impairment of full mania. Bipolar spectrum presentations — bipolar disorder NOS, cyclothymia, subthreshold hypomania, and antidepressant-induced hypomania — sit outside strict DSM-5 thresholds but respond to bipolar-directed pharmacology and reliably worsen on antidepressant monotherapy.

RECO’s evaluation uses the Mood Disorder Questionnaire (MDQ), the Hypomania Checklist (HCL-32), structured mood charting, and detailed longitudinal history — including family history, postpartum episodes, prior antidepressant response, and sleep architecture — to make the call. The MDQ has strong specificity but only moderate sensitivity for bipolar II; the HCL-32 captures the subthreshold hypomania the MDQ tends to miss. Together they anchor the interview, but neither replaces the interview itself.

The distinction changes pharmacology directly. Bipolar I typically responds to combined mood stabilizer plus second-generation antipsychotic regimens. Bipolar II depression responds well to lamotrigine and quetiapine, while lithium monotherapy in bipolar II is less consistent than the bipolar I literature suggests. Bipolar spectrum presentations require mood stabilizer cover before any SSRI or SNRI is introduced, and antidepressant monotherapy is contraindicated once cyclicity is documented.

Lithium — the treatment we take seriously when others don’t

Lithium remains the most effective long-term mood stabilizer in bipolar disorder and the only psychiatric medication with robust evidence for reduction of completed suicide. It lowers manic recurrence, depressive recurrence, and mortality across multiple randomized and observational datasets. Prescribing rates have nonetheless fallen — largely because the monitoring feels burdensome to practices without the infrastructure to run it.

RECO’s protocol builds monitoring in from the start. Baseline labs include TSH, creatinine, calcium, CBC, and pregnancy testing where relevant. Target maintenance level is 0.6-1.0 mEq/L drawn 12 hours post-dose, with more aggressive levels indicated for acute mania. Levels run every one to two weeks during titration and then quarterly once stable. TSH and renal function repeat every six months. Weight, waist circumference, and metabolic labs run annually — sooner if the trajectory suggests thyroid suppression or renal decline.

For clients who tolerate lithium — and most do, when titration is slow and dosing is nocturnal — the outcomes justify the monitoring burden. For clients who don’t tolerate it, we say so and switch. The failure mode we refuse is starting lithium, skipping the monitoring, and either driving toxicity or losing efficacy through chronic underdosing.

Second-generation antipsychotics and where they fit

Several second-generation antipsychotics carry FDA approval for defined phases of bipolar disorder. Quetiapine has indications across bipolar depression, mania, and maintenance. Lurasidone is approved for bipolar depression with a comparatively favorable metabolic profile. Aripiprazole covers mania and maintenance and is used adjunctively in bipolar depression. Olanzapine and the olanzapine-fluoxetine combination cover bipolar depression and mania but carry the heaviest metabolic burden of the class. Risperidone and cariprazine are established mania options; cariprazine also has bipolar depression data.

Choice is driven by phase — acute depression, acute mania, maintenance — plus tolerability profile (sedation, weight, prolactin, akathisia, EPS), prior response history, and comorbidity. A client with metabolic syndrome and a predominantly depressive course is a different case from a client with a predominantly manic course and recent psychotic features. The prescription reflects that.

Metabolic monitoring is standard. Baseline and follow-up weight, waist circumference, fasting glucose or HbA1c, lipid panel, and blood pressure run at intervals defined by the ADA/APA consensus. Prolactin and movement disorder screening with AIMS run where clinically indicated. Antipsychotics deliver meaningful outcomes in bipolar disorder — provided the practice running them tracks what they do to the rest of the body.

Lamotrigine, valproate, and the anticonvulsant options

Lamotrigine has the strongest evidence for bipolar II depression and for maintenance in bipolar disorder where depression is the predominant pole. It is not effective for acute mania. The titration schedule — 25 mg for two weeks, 50 mg for two weeks, then doubling toward 200 mg — is dictated by Stevens-Johnson syndrome risk. Any deviation, including missed doses of more than five days or the introduction of interacting agents such as valproate, requires restarting titration from the beginning.

Valproate is effective for mania, mixed states, and rapid cycling. Monitoring covers LFTs, platelets, ammonia when clinically suggested, and serum levels with a typical maintenance target of 50-125 mcg/mL. Valproate is contraindicated in pregnancy and in women of reproductive potential without effective contraception due to teratogenicity and neurodevelopmental risk to the fetus. That constraint is discussed explicitly at initiation, not deferred.

Carbamazepine and oxcarbazepine sit as second-line options, useful in mixed states and rapid cycling but carrying substantial CYP3A4 induction interactions and HLA-B*1502 testing recommendations in relevant populations. Each anticonvulsant used in bipolar disorder has a defined monitoring protocol, and RECO runs each of them rather than defaulting to whichever agent is easiest to prescribe.

What to expect on your first visit

The initial evaluation is 60-90 minutes with a board-certified psychiatric prescriber. It covers longitudinal mood history, prior medication trials with doses and response, sleep, substance use, medical history, family psychiatric history, current stressors, and structured screening — PHQ-9, GAD-7, MDQ, HCL-32, and ASRS where ADHD is a differential. Baseline labs are ordered where diagnostically or pharmacologically relevant.

The output of that visit is a written diagnostic formulation, a medication plan with rationale, and a monitoring schedule. Where psychotherapy is indicated — interpersonal and social rhythm therapy (IPSRT), family-focused therapy, or CBT adapted for bipolar disorder — referrals are made to therapists with genuine bipolar competency rather than general anxiety-and-depression practices.

Insurance and getting to Delray Beach from Palm Beach Gardens

RECO Integrated Psychiatry is in-network with Florida Blue, Aetna, Cigna, UnitedHealthcare, Humana, and BCBS. Benefits are verified before the first appointment and typical out-of-pocket costs are quoted in writing. From PGA National, Mirasol, BallenIsles, Frenchman’s Reserve, or Old Palm, the drive is I-95 south to Atlantic Avenue — 35 minutes off-peak and closer to 50 during rush hour.

Once the medication plan is established and mood is stable, telepsychiatry follow-ups are available to Palm Beach County residents who prefer to reduce driving frequency. Lab draws for lithium levels, LFTs, and metabolic monitoring can run through a local plan-covered outpatient lab so results flow back to RECO without an additional trip south.

Serving residents of: BallenIsles, Frenchman's Reserve, Mirasol, Old Palm, PGA National.